Cancer incidence and mortality in women receiving estrogen and estrogen- progestin replacement therapy - Long-term follow-up of a Swedish cohort

International Journal of Cancer

Volumn 67, Issue 3, 1996, Pages 327-332

  Persson, Ingemar ^a   Yuen, Jonathan ^a   Bergkvist, Leif ^a   Schairer, Catherine ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GESTAGEN;

ADULT; ARTICLE; BILIARY TRACT CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; COLORECTAL CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HORMONE SUBSTITUTION; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; UTERUS CANCER;

AGED; BREAST NEOPLASMS; COHORT STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS; PROGESTINS; REGISTRIES; SWEDEN; TIME FACTORS;

EID: 0029809730     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.3.CO;2-J     Document Type: Article

References (30)

1. ADAMI, H.O., PERSSON, I., HOOVER, R., SCHAIRER, C. and BERGKVIST, L., Risk of cancer in women receiving hormone replacement therapy. Int. J. Cancer, 44, 833-839 (1989).
2. BERGKVIST, L., ADAMI, H.O., PERSSON, I., BERGSTROM, R. and KRUSEMO, U.B., Prognosis, after breast cancer diagnosed in women exposed to estrogen and estrogen-progestogen replacement therapy. Amer. J. Epidemiol., 130, 221-228 (1989a).
3. BERGKVIST, L., ADAMI, H.O., PERSSON, I., HOOVER, R. and SCHAIRER, C., The risk of breast cancer after estrogen and estrogen-progestin replacement. New Engl. J. Med., 321, 293-297 (1989b).
4. BERGKVIST, L., ADAMI, H.O., PERSSON, I. and SCHAIRER, C., Risk factors for breast and endometrial cancer in a cohort of women treated with menopausal estrogen. Int. J. Epidemiol., 17, 732-737 (1988).
5. BRINTON, L.A., HOOVER, R.N. and THE ENDOMETRIAL CANCER COLLABORATIVE GROUP, Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet. Gynecol., 81, 265-271 (1993).
6. BRINTON, L.A. and SCHAIRER, C., Estrogen replacement therapy and breast cancer risk. Epidemiol. Rev., 15, 66-79 (1993).
7. CALLE, E.E., MIRACLE-MCMAHILL, H.L., THUN, M.J. and HEATH, C.W., Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J. natl. Cancer Inst., 87, 517-523 (1995).
8. CHUTE, C.G., WILLET, W.C., COLDITZ, G.A., STAMPFER, M.J., ROSNER, B. and SPEIZER, F.E., A prospective study of reproductive history and exogenous estrogens on the risk of colorectal cancer in women. Epidemiology, 2, 201-207 (1991).
9. COLDITZ, C.A., HANKINSON, S.E., HUNTER, D.J., WILLETT, W.C., MANSON, J.E., STAMPFER, M.J., HENNEKENS, C., ROSNER, B. and SPEIZER, T.E., The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl. J. Med., 332, 1589-1593 (1995).
10. DEVESA, S.S. and SILVERMAN, D.T., Protective effect of oestrogen in pancreatic cancer. Lancet, II, 905-906 (1988).
11. FALKEBORN, M., PERSSON, I., ADAMI, H.O., BERGSTROM, R., EAKER, E., LITHELL, H., MOHSEN, R. and NAESSEN, T., The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Brit. J. Obstet. Gynaecol., 99, 821-828 (1992).
12. GRADY, D., RUBIN, S.M., PETITTI, D.B., FOX, C.S., BLACK, D., ETTINGER, B., ERNSTER, V.L. and CUMMINGS, S.R., Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann intern. Med., 117, 1016-1037 (1992).
13. HOLLY, E.A., CRESS, R.D. and AHN, D.K., Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol. Biomark. Prev., 3, 661-668 (1994).
14. HULKA, B.S., LIU, E.T. and LININGER, R.A., Steroid hormones and risk of breast cancer. Cancer, Suppl., 74, 1111-1124 (1994).
15. JACOBS, E.J., WHITE, E. and WEISS, N.S., Exogenous hormones, reproductive history, and colon cancer. Cancer Causes Contr., 5, 359-366 (1994).
16. JICK, S.S., WALKER, A.M. and JICK, H., Estrogens, progesterone, and endometrial cancer. Epidemiology, 4, 20-24 (1993).
17. LINDBLAD, P., MELLEMGAARD, A., SCHLEHOFER, B., ADAMI, H.O., MCCREDIE, M., MCLAUGHLIN, J.K. and MANDEL, J.S., International renal-cell cancer study: reproductive factors, gynecologic operations and exogenous hormones. Int. J. Cancer, 61, 192-198 (1995).
18. MOGUILEWSKY, M., PERTUISET, B.F., VERZAT, C., PHILIBERT, D., PHILIPPON, J. and POISSON, M., Cytosolic and nuclear sex steroid receptors in meningioma. Clin. Neuropharmacol., 7, 375-381 (1984).
19. NEWCOMB, P.A., LONGNECKER, M.P., STORER, B.E., MITTENDORF, R., BARON, J., CLAPP, R.W., BOGDAN, G. and WILLETT, W.C., Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Amer. J. Epidemiol., 142, 788-795 (1995).
20. PERSSON, I., ADAMI, H.O., BERGKVIST, L., LINDGREN, A., PETTERSON, B., HOOVER, A. and SCHAIRER, C., Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Brit. med. J., 298, 147-151 (1989).
21. PERSSON, I., ADAMI, H.O., JOHANSSON, E.D.B., LINDBERG, B.S., MANELL, P. and WESTERHOLM, B., A cohort study on estrogen treatment and risk of endometrial cancer: evaluation of method and its applicability. Europ. J. clin. Pharmacol., 25, 625-632 (1983a).
22. PERSSON, I., ADAMI, H.O., LINDBERG, B.S., JOHANSSON, E.D.B. and MANELL, P., Practice and patterns of estrogen treatment in climacteric women in a Swedish population. A descriptive epidemiological study. Part I. Acta obstet. gynecol. scand., 62, 289-296 (1983b).
23. PERSSON, I., ADAMI, H.O., LINDBERG, B.S., JOHANSSON, E.D.B. and MANELL, P., Characteristics of estrogen-treated women: a descriptive epidemiological study of a Swedish population: Part II. Acta obstet. gynecol. Scand., 62, 297-302 (1983c).
24. PERSSON, I., YUEN, J., BERGKVIST, L., ADAMI, H.O., HOOVER, R. and SCHAIRER, C., Combined oestrogen-progestogen replacement and breast cancer risk (Letter). Lancet, 340, 8826 (1992).
25. RISCH, H.A. and HOWE, G.R., Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol., Biomarkers Prevent., 4, 21-28 (1995).
26. STANFORD, J.L. and THOMAS, D.B., Exogenous progestins and breast cancer. Epidemiol. Rev., 15, 98-107 (1993).
27. STANFORD, J.L., WEISS, N.S., VOIGT, L.F., DALING, J.R., HABEL, L.A. and ROSSING, M.A., Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J. Amer. med. Ass., 274, 137-142 (1995).
28. TRICHOPOULOS, D., Etiology of primary liver cancer and the role of steroidal hormones. Cancer Causes Contr., 3, 3-5 (1992).
29. WHITTEMORE, A.S., HARRIS, R., INTYRE, J. and THE COLLABORATIVE OVARIAN CANCER GROUP, Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Amer. J. Epidemiol., 136, 1184-1203 (1992).
30. YUEN, J., PERSSON, I., BERGKVIST, L., HOOVER, R., SCHAIRER, C. and ADAMI, H.O., Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for "healthy drug-user" effect. Cancer Causes Contr., 4, 369-374 (1993).